EMBO Molecular Medicine

Papers
(The TQCC of EMBO Molecular Medicine is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Circulating proteomic panels for risk stratification of intracranial aneurysm and its rupture345
Whole‐brain microscopy reveals distinct temporal and spatial efficacy of anti‐Aβ therapies235
THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer141
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders135
HIF2α activation and mitochondrial deficit due to iron chelation cause retinal atrophy123
Targetable Brg1‐CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking113
The state of the art of bispecific antibodies for treating human malignancies112
A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability95
Targeting the Leukemic stem cell protein machinery by inhibition of mitochondrial pyrimidine synthesis92
Flower lose, a cell fitness marker, predicts COVID‐19 prognosis84
Activation of the integrated stress response is a vulnerability for multidrug‐resistant FBXW7 ‐deficient cells77
Glomerular endothelial cell senescence drives age‐related kidney disease through PAI‐170
Targeting conformational changes in C‐reactive protein to inhibit pro‐inflammatory actions65
When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease65
Elongator and the role of its subcomplexes in human diseases64
IQCN disruption causes fertilization failure and male infertility due to manchette assembly defect62
Depressive patient‐derived GABA interneurons reveal abnormal neural activity associated with HTR2C60
Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain57
TFEB and TFE3 drive kidney cystogenesis and tumorigenesis57
Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia56
Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems54
Eosinophil‐derived IL ‐4 is necessary to establish the inflammatory structure in innate inflammation54
Diagnostic biomarkers for active tuberculosis: progress and challenges51
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers50
ASO targeting RBM3 temperature‐controlled poison exon splicing prevents neurodegeneration in vivo50
Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS‐CoV‐2 mRNA vaccination49
Systemic inflammation after stroke: implications for post‐stroke comorbidities49
Nerve regeneration by interferon intervention in aging brain48
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer48
Autosomal recessive pathogenic MSTO1 variants in hereditary optic atrophy46
Single‐cell profiling of muscle‐infiltrating T cells in idiopathic inflammatory myopathies45
Shear stress control of vascular leaks and atheromas through Tie2 activation by VE‐PTP sequestration45
Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model44
Functions of double‐negative B cells in autoimmune diseases, infections, and cancers44
ALX1 ‐related frontonasal dysplasia results from defective neural crest cell development and migration43
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T‐cell lymphoma43
Looking at a baby's heart through the lens of the mother's blood43
A coordinated multiorgan metabolic response contributes to human mitochondrial myopathy42
Mining the bacterial genome to discover new antimicrobial molecules41
Macrophage colony‐stimulating factor as a weapon against cytomegalovirus40
Optimizing the Cas13 antiviral train: cargo and delivery40
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT39
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer39
A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis38
An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV ‐236
Advances in high‐throughput mass spectrometry in drug discovery36
In vivo single‐cell transcriptomics reveal Klebsiella pneumoniae skews lung macrophages to promote infection36
Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington's disease36
The human host response to monkeypox infection: a proteomic case series study36
X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL35
Elucidating effects of environmental exposure using human‐induced pluripotent stem cell disease modeling35
A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond35
Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation34
The molecular biology of peritoneal metastatic disease34
Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis34
Sex differences and risk factors for bleeding in Alagille syndrome33
Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa33
AAV induces hepatic necroptosis and carcinoma in diabetic and obese mice dependent on Pebp1 pathway33
Rational design of West Nile virus vaccine through large replacement of 3′ UTR with internal poly(A)33
LAG3 is not expressed in human and murine neurons and does not modulate α‐synucleinopathies33
Immuno(T)herapy for age‐related diseases33
miR ‐181a/b downregulation: a mutation‐independent therapeutic approach for inherited retinal diseases32
Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis32
Trichothiodystrophy‐associated MPLKIP maintains DBR1 levels for proper lariat debranching and ectodermal differentiation32
Nanobody‐mediated complement activation to kill HIV‐infected cells32
External validity in translational biomedicine: understanding the conditions enabling the cause to have an effect32
Liver gene therapy with intein‐mediated F8 trans ‐splicing corrects mouse haemophilia A31
Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism31
IL‐27 produced during acute malaria infection regulates Plasmodium‐specific memory CD4+ T cells31
YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis31
Adaptively evolved human oral actinomyces‐sourced defensins show therapeutic potential31
Systemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease31
Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection30
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model30
A progeroid syndrome caused by a deep intronic variant in TAPT1 is revealed by RNA/SI‐NET sequencing29
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer29
TAPT1—at the crossroads of extracellular matrix and signaling in Osteogenesis imperfecta28
Dual IRE1 RNase functions dictate glioblastoma development28
NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA528
Full eradication of pre‐clinical human papilloma virus‐induced tumors by a lentiviral vaccine28
A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis28
Development of allogeneic iPS cell‐based therapy: from bench to bedside28
Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma28
Molecular and functional properties of human Plasmodium falciparum CSP C‐terminus antibodies27
A spoonful of L‐fucose—an efficient therapy for GFUS‐CDG, a new glycosylation disorder27
Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease27
Answer to Gerber et al.Autosomal recessive pathogenic MSTO1 variants in hereditary optic atrophy27
Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody26
AAV‐delivered diacylglycerol kinase DGKk achieves long‐term rescue of fragile X syndrome mouse model26
Transfixed by transgenics: how pathology assumptions are slowing progress in Alzheimer's disease and related dementia research26
Patient‐ and xenograft‐derived organoids recapitulate pediatric brain tumor features and patient treatments26
microRNAs trip down memory lane26
RNAi to treat SARS‐CoV‐2—variant proofing the next generation of therapies26
0.070823907852173